fda compounding semaglutide enforcement news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compounding pharmacies to halt semaglutide

Supplementary data The following is the Supplementary data to this article: References 1.Nouwen A., Winkley K., Twisk J., Lloyd C.E., Peyrot M., Ismail K., et al

Phone support at (888) 266-5071 is available during business hours (8am-8pm) for billing and technical questions only

provide substantial contribution to interpretation of data, critically reviewed the manuscript, contribute an important intellectual content and gave final approval of the manuscript

Because glucagon receptor activation can raise blood glucose in isolation, the simultaneous GLP-1 and GIP stimulation is essential to maintaining glycaemic safety which is one reason why retatrutide must only be used under close medical supervision

Cagrilintide Dosage with Retatrutide: Safety Considerations Overlapping Side Effect Profiles Both cagrilintide and retatrutide share remarkably similar adverse event patterns, raising legitimate concerns about potential additive effects when considering cagrilintide dosage with retatrutide combinations [9]